{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:01:03Z","timestamp":1790438463975,"version":"4.1.0"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4030180"],"award-info":[{"award-number":["4030180"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021771","name":"Student Research Committee, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117280","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T18:49:14Z","timestamp":1787078954000},"page":"117280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of chimeric antigen receptor (CAR) T cell therapy in breast cancer"],"prefix":"10.1016","volume":"188","author":[{"given":"Ahmad","family":"Farajzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Mohammad","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiar Kamal","family":"Kheder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OmeFarveh","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsane","family":"Fadaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amene","family":"Raouf-Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed-Alireza","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.intimp.2026.117280_bb0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/curroncol32030154","article-title":"Perioperative drug management of systemic therapies in breast cancer: a literature review and treatment recommendations","volume":"32","author":"Galuia","year":"2025","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cai2.46","article-title":"Advances in medical treatment of breast cancer in 2022","volume":"2","author":"Zhai","year":"2023","journal-title":"Cancer Innov."},{"key":"10.1016\/j.intimp.2026.117280_bb0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3389\/fonc.2020.00864","article-title":"Breast cancer survivorship, quality of life, and late toxicities","volume":"10","author":"Nardin","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","article-title":"Tumor immunology and tumor evolution: intertwined histories","volume":"52","author":"Galon","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-026-02568-y","article-title":"piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer","volume":"25","author":"Luo","year":"2026","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.117280_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0055","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.117280_bb0060","doi-asserted-by":"crossref","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"16","key":"10.1016\/j.intimp.2026.117280_bb0070","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers16162858","article-title":"Strategies for improving CAR T cell persistence in solid tumors","volume":"16","author":"Wittling","year":"2024","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.intimp.2026.117280_bb0075","first-page":"3322","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0080","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41467-025-59298-w","article-title":"Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunotherapy Cancer."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0090","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/cancers18060911","article-title":"Immunotherapies for breast cancer: from checkpoint inhibition to emerging cellular therapies","volume":"18","author":"Tsagkaraki","year":"2026","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.intimp.2026.117280_bb0095","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0100","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Report. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.117280_bb0105","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/cells11121974","article-title":"CAR T cell locomotion in solid tumor microenvironment","volume":"11","author":"Nguyen","year":"2022","journal-title":"Cells"},{"issue":"58","key":"10.1016\/j.intimp.2026.117280_bb0110","article-title":"Advancing breast cancer treatment through dual targeting CAR T cell therapy","volume":"17","author":"Sheikh","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.intimp.2026.117280_bb0115","doi-asserted-by":"crossref","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0120","doi-asserted-by":"crossref","first-page":"1794130","DOI":"10.3389\/fimmu.2026.1794130","article-title":"Multidimensional tumor heterogeneity and its role in therapeutic resistance","volume":"17","author":"Mubin","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0125","first-page":"58","article-title":"CAR-T design: elements and their synergistic function","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0130","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117280_bb0135","series-title":"The EBMT\/EHA CAR-T cell handbook","first-page":"3","article-title":"Structure of and signalling through chimeric antigen receptor","author":"Chabannon","year":"2022"},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb0140","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Trans. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0155","doi-asserted-by":"crossref","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0160","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178558","article-title":"IL-2\u2013inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells","volume":"135","author":"Fu","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0175","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e43","article-title":"Cytokine engineering in CAR-T cell therapy: next-generation strategies","volume":"25","author":"Kim","year":"2025","journal-title":"Immune Netw."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0180","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0185","article-title":"Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence","volume":"16","author":"Ghorai","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.intimp.2026.117280_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable smart CAR-T design: a new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","author":"Wen","year":"2026","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0195","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"44","key":"10.1016\/j.intimp.2026.117280_bb0200","doi-asserted-by":"crossref","first-page":"18874","DOI":"10.1021\/jacs.0c08538","article-title":"Enhanced safety and antitumor efficacy of switchable dual chimeric antigen receptor-engineered T cells against solid tumors through a synthetic bifunctional PD-L1-blocking peptide","volume":"142","author":"Yang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.intimp.2026.117280_bb0205","series-title":"A novel, universal targeting receptor-adaptor CAR platform demonstrates versatile, flexible, and controlled tumor inhibition in an ipsc-derived t-cell","author":"Devaney","year":"2024"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0210","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1038\/s41467-024-53996-7","article-title":"Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters","volume":"15","author":"Park","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117280_bb0215","doi-asserted-by":"crossref","first-page":"1698442","DOI":"10.3389\/fonc.2025.1698442","article-title":"Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2025","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0220","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117280_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117753","article-title":"Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy","volume":"181","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0230","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s42003-022-04262-3","article-title":"Mechanisms of circular RNA degradation","volume":"5","author":"Ren","year":"2022","journal-title":"Commun. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41419-024-06698-3","article-title":"The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications","volume":"15","author":"Ma","year":"2024","journal-title":"Cell Death Dis."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2026.117280_bb0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","article-title":"Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors","volume":"39","author":"Gutierrez","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7643","key":"10.1016\/j.intimp.2026.117280_bb0245","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7786","key":"10.1016\/j.intimp.2026.117280_bb0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0260","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0265","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0270","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40779-024-00582-z","article-title":"Targeting RTKs\/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials","volume":"11","author":"Mehta","year":"2024","journal-title":"Military Med. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer."},{"issue":"13","key":"10.1016\/j.intimp.2026.117280_bb0280","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.18632\/oncotarget.2209","article-title":"Deregulation of the EGFR\/PI3K\/PTEN\/Akt\/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention","volume":"5","author":"Davis","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.117280_bb0285","doi-asserted-by":"crossref","first-page":"1446414","DOI":"10.3389\/fphar.2024.1446414","article-title":"HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"9_Supplement","key":"10.1016\/j.intimp.2026.117280_bb0290","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO5-04-06","article-title":"Abstract PO5-04-06: enhancing antitumor activity of Her2 CAR T cells through TR2BB co-expression and cytokine signal 3 incorporation","volume":"84","author":"Chamorro","year":"2024","journal-title":"Cancer Res."},{"issue":"8_Supplement_1","key":"10.1016\/j.intimp.2026.117280_bb0295","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1538-7445.AM2025-6118","article-title":"Engineering p95HER2 CAR T cells for the treatment of HER2-positive tumors","volume":"85","author":"Grinyo-Escuer","year":"2025","journal-title":"Cancer Res."},{"issue":"Supplement_5","key":"10.1016\/j.intimp.2026.117280_bb0300","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf201.0464","volume":"27","author":"Portnow","year":"2025","journal-title":"Neuro-Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2 thorn breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0315","first-page":"A1","article-title":"324 Allogeneic CAR T cells targeting Liv-1 for breast cancer","volume":"11","author":"Zakas","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.117280_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113920","article-title":"Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer","volume":"201","author":"Tarantino","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-20-0405","article-title":"Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition","volume":"9","author":"Xia","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0330","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-022-06783-1","article-title":"EGFR as a potent CAR T target in triple negative breast cancer brain metastases","volume":"197","author":"Subham","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0340","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0345","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","article-title":"Understanding the biology of HER3 receptor as a therapeutic target in human cancer","volume":"8","author":"Lyu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0350","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.intimp.2026.117280_bb0355","first-page":"9","article-title":"60P Expression of antibody-drug conjugate targets in metastatic breast cancer","author":"Borremans","year":"2024","journal-title":"ESMO Open."},{"issue":"36","key":"10.1016\/j.intimp.2026.117280_bb0360","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3\u2013directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3\u2013expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117280_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115081","article-title":"Immune marker expression and prognosis of early breast cancer expressing HER3","volume":"213","author":"Lee","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.intimp.2026.117280_bb0370","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-23-0020","article-title":"Frequent overexpression of HER3 in brain metastases from breast and lung cancer","volume":"29","author":"Tomasich","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0375","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.117280_bb0380","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7150\/thno.15083","article-title":"Gas6\/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt\/GSK-3\u03b2\/\u03b2-catenin signaling","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0385","article-title":"AXL as a target in breast cancer therapy","volume":"2020","author":"Colavito","year":"2020","journal-title":"J. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/13543784.2025.2511178","article-title":"Prospects of current AXL-targeting therapies in early phase cancer trials","volume":"34","author":"Yim","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0395","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.intimp.2026.117280_bb0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117280_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100204","article-title":"Targeting c-Met in breast cancer: from mechanisms of chemoresistance to novel therapeutic strategies","volume":"7","author":"Iweala","year":"2024","journal-title":"Curr. Res. Pharm. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117280_bb0415","article-title":"Unlocking c-MET: a comprehensive journey into targeted therapies for breast cancer","volume":"588","author":"Kaboli","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0420","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The clinical and functional significance of c-Met in breast cancer: a review","volume":"17","author":"Ho-Yen","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0425","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7150\/ijbs.76187","article-title":"Targeting breast cancer stem cells","volume":"19","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117280_bb0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.prp.2014.04.002","article-title":"MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting","volume":"210","author":"Koh","year":"2014","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0435","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2013.31","article-title":"High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer","volume":"108","author":"Zagouri","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.intimp.2026.117280_bb0440","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1038\/s41388-020-1193-8","article-title":"MET targeting: time for a rematch","volume":"39","author":"Koch","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0445","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-025-06475-6","article-title":"Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models","volume":"23","author":"Qin","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-022-02479-y","article-title":"Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy","volume":"41","author":"Chiriaco","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0455","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0460","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0465","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10549-023-06914-2","article-title":"Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial","volume":"199","author":"Parker","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0470","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117280_bb0475","doi-asserted-by":"crossref","first-page":"1121020","DOI":"10.3389\/fmed.2023.1121020","article-title":"Anti-ROR1 CAR-T cells: Architecture and performance","volume":"10","author":"Osorio-Rodriguez","year":"2023","journal-title":"Front. Med. (Lausanne)."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0480","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","article-title":"Therapeutic advances in the targeting of ROR1 in hematological cancers","volume":"10","author":"Tigu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0485","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-022-01531-1","article-title":"Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC","volume":"24","author":"Harrasser","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer (vol 8, e000676, 2020)","volume":"8","author":"Stuber","year":"2020","journal-title":"J. Immunother. Cancer."},{"issue":"18","key":"10.1016\/j.intimp.2026.117280_bb0495","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI","volume":"4","author":"Wallstabe","year":"2019","journal-title":"Insight"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0500","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12672-024-01159-x","article-title":"Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment","volume":"15","author":"Chen","year":"2024","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051357","article-title":"Challenges of anti-mesothelin CAR-T-cell therapy","volume":"15","author":"Zhai","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0510","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1245\/s10434-025-17117-y","article-title":"Mesothelin (MSLN) is highly expressed in triple negative breast cancer and is associated with enhanced cell proliferation and proinflammatory tumor microenvironment","volume":"32","author":"Hagerty","year":"2025","journal-title":"Ann. Surg. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2026.117280_bb0515","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202439119","article-title":"Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0520","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-025-00621-y","article-title":"Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer","volume":"14","author":"Saliu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117280_bb0525","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Therapy Oncol."},{"key":"10.1016\/j.intimp.2026.117280_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104262","article-title":"The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth","volume":"360","author":"Yang","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111631","article-title":"Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer","volume":"129","author":"Somboonpatarakun","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0540","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-025-14402-7","article-title":"From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer\u2013insights from the national cancer institute","volume":"25","author":"Ebrahim","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.117280_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1292211","article-title":"Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2026.117280_bb0550","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117280_bb0555","doi-asserted-by":"crossref","first-page":"1292211","DOI":"10.3389\/fonc.2023.1292211","article-title":"Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements","volume":"13","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012442","article-title":"Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunotherapy Cancer."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0565","doi-asserted-by":"crossref","first-page":"549","DOI":"10.21873\/cgp.20471","article-title":"GD2 in breast cancer: a potential biomarker and therapeutic target","volume":"21","author":"Mokbel","year":"2024","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0570","doi-asserted-by":"crossref","first-page":"1683345","DOI":"10.1080\/2162402X.2019.1683345","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2020","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0575","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-017-2045-4","article-title":"CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target","volume":"66","author":"Holzinger","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.117280_bb0580","doi-asserted-by":"crossref","first-page":"1499471","DOI":"10.3389\/fimmu.2024.1499471","article-title":"Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy","volume":"15","author":"Aniogo","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0585","doi-asserted-by":"crossref","first-page":"1509675","DOI":"10.3389\/fpubh.2025.1509675","article-title":"Unveiling the impact of CD133 on cell cycle regulation in radio-and chemo-resistance of cancer stem cells","volume":"13","author":"Wu","year":"2025","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0590","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-23-1735","article-title":"Intratumoral delivery of chimeric antigen receptor T cells targeting CD133 effectively treats brain metastases","volume":"30","author":"Kieliszek","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0595","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0600","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10549-025-07860-x","article-title":"Mesothelin-expressing triple-negative breast cancer: a highly invasive and immunosuppressive subtype","volume":"215","author":"Zhao","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.intimp.2026.117280_bb0605","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/14737140.2024.2443009","article-title":"Post-operative serum CEA predicts prognosis in HR-positive\/HER2-negative early breast cancer","volume":"24","author":"Kavgaci","year":"2024","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0610","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41698-025-01016-2","article-title":"Mucin-1: a promising pan-cancer therapeutic target","volume":"9","author":"Grewal","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0615","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/biom12070952","article-title":"Advances in MUC1-Mediated Breast Cancer Immunotherapy","volume":"12","author":"Li","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0620","first-page":"2449373","article-title":"An in vitro comparison of costimulatory domains in chimeric antigen receptor T cell for breast cancer treatment","volume":"2022","author":"Khuisangeam","year":"2022","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0625","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40425-018-0347-5","article-title":"CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation","volume":"6","author":"Bajgain","year":"2018","journal-title":"J. Immunother. Cancer."},{"issue":"7_Supplement","key":"10.1016\/j.intimp.2026.117280_bb0630","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/1538-7445.AM2023-1779","article-title":"Fourth-generation chimeric antigen receptor T cells targeting mucin 1 against breast cancer","volume":"83","author":"Supimon","year":"2023","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0635","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.3390\/ijms23116122","article-title":"EpCAM- and EGFR-specific antibody drug conjugates for triple-negative breast cancer treatment","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0640","doi-asserted-by":"crossref","first-page":"2540599","DOI":"10.1080\/07853890.2025.2540599","article-title":"EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer","volume":"57","author":"Furusawa","year":"2025","journal-title":"Ann. Med."},{"issue":"48","key":"10.1016\/j.intimp.2026.117280_bb0645","doi-asserted-by":"crossref","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.117280_bb0650","doi-asserted-by":"crossref","first-page":"1176647","DOI":"10.3389\/fimmu.2023.1176647","article-title":"Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0655","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12943-024-02150-4","article-title":"Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR","volume":"23","author":"Kang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0660","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0665","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13046-025-03475-8","article-title":"B7-H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer","volume":"44","author":"Cattaneo","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011533","article-title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer","volume":"13","author":"Stucchi","year":"2025","journal-title":"J. Immunotherapy Cancer."},{"issue":"23","key":"10.1016\/j.intimp.2026.117280_bb0675","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.3390\/ijms20235942","article-title":"Cspg4 as target for CAR-T-cell therapy of various tumor entities\u2013merits and challenges","volume":"20","author":"Harrer","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2026.117280_bb0680","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.117280_bb0685","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2026.117280_bb0695","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.3390\/ijms241713156","article-title":"Targeting NKG2DL with bispecific NKG2D\u2013CD16 and NKG2D\u2013CD3 fusion proteins on triple\u2013negative breast cancer","volume":"24","author":"Kaidun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0700","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb0705","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/biomedicines13092314","article-title":"Allogeneic NKG2D CAR-T cell therapy: a promising approach for treating solid tumors","volume":"13","author":"Mukhametshin","year":"2025","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0710","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance","volume":"40","author":"Yousefi","year":"2021","journal-title":"Oncogene"},{"issue":"12_Supplement","key":"10.1016\/j.intimp.2026.117280_bb0715","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1538-7445.AM2022-577","article-title":"Control of solid tumors by alphav beta3 CAR T cells is accompanied by profound tumor penetration and prevention of metastasis in pre-clinical models","volume":"82","author":"Cobb","year":"2022","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0720","first-page":"2","article-title":"Control of orthotopic melanoma and breast tumor growth and metastases is achieved by alpha<sub>v<\/sub> beta<sub>3<\/sub> CAR T cells and is augmented via PD-1 blockade","volume":"83","author":"Cobb","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.11","article-title":"CAR T cells targeting \u03b1(v)\u03b2(3) integrin are effective against advanced cancer in preclinical models","volume":"1","author":"Wallstabe","year":"2018","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.intimp.2026.117280_bb0735","first-page":"OF1","article-title":"\u03b1v\u03b23 CAR-T cells simultaneously targeting tumor and metastases produce highly effective control in preclinical models of melanoma and triple-negative breast cancer","author":"Cobb","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"12_Supplement","key":"10.1016\/j.intimp.2026.117280_bb0740","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1538-7445.AM2022-577","article-title":"Abstract 577: Control of solid tumors by alphav beta3 CAR T cells is accompanied by profound tumor penetration and prevention of metastasis in pre-clinical models","volume":"82","author":"Cobb","year":"2022","journal-title":"Cancer Res."},{"issue":"7_Supplement","key":"10.1016\/j.intimp.2026.117280_bb0745","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1538-7445.AM2023-4101","article-title":"Abstract 4101: control of orthotopic melanoma and breast tumor growth and metastases is achieved by alphav beta3 CAR T cells and is augmented via PD-1 blockade","volume":"83","author":"Cobb","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0750","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1038\/s41467-025-61775-1","article-title":"Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design","volume":"16","author":"Wasinska-Kalwa","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117280_bb0755","unstructured":"Lyell immunopharma reports dose-dependent clinical activity from phase 1 trial of LYL797, a ROR1-targeted CAR-T cell product candidate enhanced with its proprietary anti-exhaustion technology [press release]. 2024."},{"issue":"12","key":"10.1016\/j.intimp.2026.117280_bb0760","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0765","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.117280_bb0770","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2024.42.16_suppl.1089","article-title":"Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0775","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117280_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2026.117280_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217771","article-title":"The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency","volume":"626","author":"Bao","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0790","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0795","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","article-title":"Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence","volume":"40","author":"Belk","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.intimp.2026.117280_bb0805","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor t cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0810","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell."},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb0815","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6481","key":"10.1016\/j.intimp.2026.117280_bb0820","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0825","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb0830","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"issue":"20 Pt 1","key":"10.1016\/j.intimp.2026.117280_bb0835","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0840","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0845","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0850","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12254-016-0292-2","article-title":"PD-L1 testing, fit for routine evaluation? From a pathologist\u2019s point of view","volume":"9","author":"Hutarew","year":"2016","journal-title":"Memo"},{"issue":"261","key":"10.1016\/j.intimp.2026.117280_bb0855","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0860","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0865","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0870","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.xphs.2020.12.015","article-title":"Addressing patient to patient variability for autologous CAR T therapies","volume":"110","author":"Jiang","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.117280_bb0875","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0880","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coi.2014.01.006","article-title":"Metabolism of activated T lymphocytes","volume":"27","author":"Maciolek","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb0885","series-title":"Tumor microenvironment (TME) and tumor immune microenvironment (TIME): new perspectives for prognosis and therapy","first-page":"971275","author":"Ramos","year":"2022"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0890","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J. Immunotherapy Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0895","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s44178-025-00205-0","article-title":"Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors","volume":"4","author":"Nie","year":"2025","journal-title":"Holist. Integr. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb0900","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0905","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/cancers13061229","article-title":"Metabolic and mitochondrial functioning in chimeric antigen receptor (CAR)\u2014T cells","volume":"13","author":"Rad Sm","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0910","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb0915","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-024-00495-6","article-title":"Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies","volume":"13","author":"Wang","year":"2024","journal-title":"Exp. Hematol Oncol."},{"key":"10.1016\/j.intimp.2026.117280_bb0920","doi-asserted-by":"crossref","first-page":"2386187","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0925","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J. Gene Med."},{"issue":"5644","key":"10.1016\/j.intimp.2026.117280_bb0930","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0935","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0940","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0945","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2026.117280_bb0950","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117280_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114609","article-title":"Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer","volume":"162","author":"He","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb0965","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"issue":"52","key":"10.1016\/j.intimp.2026.117280_bb0970","doi-asserted-by":"crossref","first-page":"89998","DOI":"10.18632\/oncotarget.21286","article-title":"Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer","volume":"8","author":"Kistner","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0975","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4161\/onci.20492","article-title":"High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes","volume":"1","author":"Martinet","year":"2012","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb0980","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117280_bb0985","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb0990","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb0995","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.intimp.2026.117280_bb1000","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb1005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb1010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb1015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb1020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","article-title":"Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy","volume":"99","author":"Komohara","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"15","key":"10.1016\/j.intimp.2026.117280_bb1025","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1158\/0008-5472.CAN-14-3443","article-title":"Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity","volume":"75","author":"Mussai","year":"2015","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb1030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm.3286","article-title":"Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity","volume":"19","author":"Liu","year":"2013","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.intimp.2026.117280_bb1035","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","article-title":"Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition","volume":"20","author":"Perna","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.intimp.2026.117280_bb1045","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb1050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.intimp.2026.117280_bb1055","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.4049\/jimmunol.1103019","article-title":"Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-\u03b3 and GM-CSF","volume":"188","author":"Spear","year":"2012","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117280_bb1060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1065","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb1070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jitc-2021-003237","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J. Immunother. Cancer."},{"issue":"7","key":"10.1016\/j.intimp.2026.117280_bb1075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2<sup>+<\/sup> macrophages associate with CD8<sup>+<\/sup> T&#xa0;cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb1080","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb1085","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb1090","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","article-title":"A single-cell atlas of the tumor and immune ecosystem of human breast cancer","volume":"177","author":"Wagner","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb1095","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb1100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","article-title":"Advances in engineered macrophages: a new frontier in cancer immunotherapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb1110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb1125","article-title":"Chimeric antigen receptor-macrophage therapy enters the clinic: the first-in-human trial for HER2(+) solid tumors","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.intimp.2026.117280_bb1130","article-title":"Myeloid cells in the era of cancer immunotherapy: top 3 unanswered questions","volume":"244","author":"Tanveer","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"23","key":"10.1016\/j.intimp.2026.117280_bb1140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117280_bb1145","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2013.00212","article-title":"Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease","volume":"4","author":"Whiteside","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb1150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb1155","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb1160","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1158\/0008-5472.CAN-04-3332","article-title":"Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells","volume":"65","author":"Beppu","year":"2005","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb1165","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117280_bb1170","first-page":"259","article-title":"Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma","volume":"20","author":"Wu","year":"2023","journal-title":"Bioact. Mater."},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb1175","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2026.117280_bb1180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb1185","article-title":"Tumor microenvironment: a complex landscape of cancer development and drug resistance","volume":"17","author":"Fatima","year":"2025","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.intimp.2026.117280_bb1190","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2026.117280_bb1195","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"issue":"19","key":"10.1016\/j.intimp.2026.117280_bb1200","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2026.117280_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114609","article-title":"Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer","volume":"162","author":"He","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.117280_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.117280_bb1215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"7764","key":"10.1016\/j.intimp.2026.117280_bb1220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2026.117280_bb1230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060194","article-title":"TGF-\u03b2 in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117280_bb1235","doi-asserted-by":"crossref","first-page":"1709852","DOI":"10.3389\/fimmu.2025.1709852","article-title":"Terminally exhausted CD8(+) T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117280_bb1240","doi-asserted-by":"crossref","first-page":"6616391","DOI":"10.1155\/2021\/6616391","article-title":"T cell exhaustion and CAR-T immunotherapy in hematological malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2026.117280_bb1245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2016.11.005","article-title":"Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade","volume":"4","author":"Serganova","year":"2017","journal-title":"Mol. Ther. Onco."},{"issue":"25","key":"10.1016\/j.intimp.2026.117280_bb1250","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb1255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"issue":"6537","key":"10.1016\/j.intimp.2026.117280_bb1260","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"46","key":"10.1016\/j.intimp.2026.117280_bb1265","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117280_bb1270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117280_bb1275","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.117280_bb1280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117280_bb1285","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117280_bb1290","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1097\/JS9.0000000000003988","article-title":"Chimeric antigen receptor T-cell therapy in patients with lymphoma: a machine learning-driven decadal informatics network analysis","volume":"112","author":"Guo","year":"2026","journal-title":"Int. J. Surg."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:37:17Z","timestamp":1790437037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":258,"alternative-id":["S1567576926011264"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117280","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of chimeric antigen receptor (CAR) T cell therapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117280"}}